Pharma & Biotech

Health

Panmure Liberum initiates PureTech Health with 'buy' and 200p target as shares trade at 40% discount to underlying value

By Ian Lyall 1d

Health

US bank expects AstraZeneca to beat third-quarter forecasts as path clears to key lung cancer data

By Ian Lyall 1d

Health

AstraZeneca and Daiichi Sankyo team up with Summit on ivonescimab trials

By Ian Lyall 6d

Health

Lilly's triple GLP-1 combination raises the stakes for Novo Nordisk

By Ian Lyall 01/10

Health

Brokers applaud AstraZeneca's $2bn Summit bet

By Ian Lyall 29/09

Health

GSK's cancer pipeline undervalued, says Jefferies after science chief chat

By Ian Lyall 29/09

Health

AstraZeneca takes $2bn stake in Summit Therapeutics to pair up cancer drugs

By Ian Lyall 29/09

Health

AstraZeneca bladder cancer combination wins FDA priority review

By Ian Lyall 25/09

Health

Hikma hires ViiV Healthcare finance chief as CFO

By Ian Lyall 24/09

Health

AstraZeneca wins EU approval for Trixeo asthma inhaler

By Ian Lyall 23/09

Health

GLP-1 maker Novo Nordisk fails to win over analysts at strategy day

By Ian Lyall 22/09

Health

PureTech blood cancer drug wins FDA fast track and clears path to phase 2

By Ian Lyall 21/09

Health

AstraZeneca wins EU backing for weekly self-injected myasthenia gravis drug

By Ian Lyall 21/09

Health

AstraZeneca shares oversold after trial flops and merger talk, analysts reckon

By Ian Lyall 16/09

Health

JP Morgan says AstraZeneca's 2027 pipeline could power growth past 2030

By Ian Lyall 16/09

Health

GSK strikes deal worth up to $750 million for cancer drug

By Ian Lyall 15/09

Health

Roche sequencer poses little threat to Oxford Nanopore, expert tells Citi

A genomics specialist hosted by the bank backs Oxford Nanopore's position and rates it above rival Pacific Biosciences

By Ian Lyall 14/09

Health

AstraZeneca breast cancer drug fails trial but Citi keeps buy rating

Analysts say the SERENA-4 setback for camizestrant does little damage and maintain their £178 target price on the shares

By Ian Lyall 14/09

Health

GSK drug cuts death risk by 54% in small cell lung cancer trial

By Ian Lyall 14/09

Health

AstraZeneca's $5bn drug promise is no 'buy' signal for Deutsche

By Ian Lyall 10/09